Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index; none of the 17 sources its claims cite is checked for support yet.
Abstract
Introduction Thrombotic microangiopathy (TMA) is characterized by the classical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Complement inhibition with eculizumab is highly efficacious in TMA secondary to complement dysregulation. However, a growing number of eculizumab-nonresponsive TMAs are reported. Recently, a syndromic form of TMA due to recessive variants in RNA exosome components ( EXOSC3 and EXOSC5 ) has been identified. The underlying pathogenesis remains unclear. Methods We identified 34 children across Europe with pontocerebellar hypoplasia 1b (PCH1b) due to EXOSC3 rare variants and reviewed their clinical history for signs of TMA. To further examine the pathogenesis, a tamoxifen-inducible whole-body Exosc3 conditional knockout mouse model ( Exosc3 KO ) was used. Results Thirteen (eight male, five female) cases of EXOSC3-TMA were identified. In the United Kingdom, the incidence of EXOSC3-TMA was 0.004/million/year. Three children received long-term eculizumab therapy: one child failed to respond and two relapsed on treatment. Exosc3 KO demonstrated cell-cycle arrest and apoptosis resulting in death in a median of eight days, with sequelae noted in actively dividing cells in the bone marrow and large intestine. In this timeframe, no kidney pathology was identified. Conclusions EXOSC3-TMA is a severe, early-onset, C5 inhibitor–resistant TMA. EXOSC3-TMA should be considered in eculizumab-resistant pediatric TMA, particularly in the context of neurodevelopmental disease.
Overview
CoChat Summary
TL;DR
Biallelic pathogenic variants in EXOSC3 cause a syndromic form of thrombotic microangiopathy (TMA) in children with pontocerebellar hypoplasia 1b, and this TMA does not respond to terminal complement inhibition with eculizumab. An inducible whole-body Exosc3 knockout mouse shows ribosome-dysfunction sequelae—cell-cycle arrest and apoptosis in rapidly dividing tissues—but does not itself develop kidney TMA.
Key findings
- TMA was detected in 13 of 34 children (8 male, 5 female) with biallelic EXOSC3 variants; median age at initial TMA presentation was 6 months (range 2–20 months), and all 17 TMA episodes were triggered within 10 days of a preceding infection, most commonly respiratory (n = 11). In the UK, incidence was 0.004/million/year; 10 patients were homozygous and 3 compound heterozygous, and two missense variants accounted for 88% of EXOSC3 alleles in the TMA subgroup (not significantly different from the non-TMA cohort).
- Clinical outcomes were poor: 11 children with TMA died during follow-up (mean age at death 10 months; range 2–43 months), 8 of 13 had renal function recovery, and 2 required long-term renal replacement. No evidence of complement dysregulation was detected.
- Eculizumab had no clear role: among 3 children treated with long-term eculizumab, 1 had no response and 2 relapsed on treatment; 2 additional patients received limited doses discontinued because of poor neurologic prognosis.
- In Exosc3 KO mice, recombination caused rapid weight loss and euthanasia at a median of 8 ± 2 days, with aplastic anemia (mean hemoglobin 89 vs 126 g/l; white blood cells 2.50×10^6 vs 7.18×10^6 cells/ml; platelets 6.12×10^8 vs 1.36×10^9 cells/ml; marrow cells 4.6×10^6 vs 2.5×10^7; reticulocytes 0.45% vs 3.48%), G0/G1 cell-cycle arrest, and increased apoptosis; no renal disease was seen in this period.
Methods
- Clinical cohort: 34 children with PCH1b and confirmed EXOSC3 rare variants identified through pan-European registries and the UK national aHUS service; clinical history reviewed for TMA, and available samples tested for known genetic and acquired (factor H autoantibodies) causes of complement-mediated atypical HUS.
- Mouse model: adult (>6 weeks) tamoxifen-inducible whole-body Exosc3 conditional knockout (Exosc3 fl) treated with intraperitoneal tamoxifen; recombination confirmed by GFP flow cytometry; hematology/biochemistry, BrdU cell-cycle flow cytometry, apoptosis flow cytometry, and histology performed.
- Analysis: clinical characteristics and outcomes described; mouse comparisons used unpaired t tests as reported in figure legends.
Limitations
- Stated: the Exosc3 KO mouse did not develop TMA; the authors attribute this to differences from human disease, including mouse age, genetic background (complete knockout vs. hypomorphic/missense alleles), and the need for an infectious trigger, and they note that a patient-specific model and/or viral stressor may be required.
- Stated: adult mice were used to avoid developmental phenotype complications, and complete Exosc3 disruption produced overwhelming cell-cycle arrest/apoptosis in rapidly dividing tissues; all reported EXOSC3 disease involves at least one missense variant with residual exosome function, and constitutive Exosc3 knockout is embryonic lethal.
- Evident: the human TMA cohort is small (13 affected children), relies on registry/clinical history and available samples, and lacks a patient-specific mechanistic model; the mouse model does not reproduce the kidney TMA phenotype.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
0 Valid · 0 Not valid · 14 Not checked · 36 Own results and interpretations
In the paper
“Histologic examination demonstrated the downstream effects of ribosome dysfunction in affected tissues, 16 with hypocellular bone marrow, thymus, and large intestine (i.e., rapidly dividing cells).”
§ Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney > Exosc3 KO mouse
What the sources say
- Not checked yetcites [16] Kampen KR, Sulima SO, Vereecke S, De Keersmaecker K. Hallmarks of ribosomopathies. Nucleic Acids Res. 2020;48:1013-1028. source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One novel in-frame deletion (c.341_343del) was identified; the remaining variants have all been identified in individuals with PCH1b.13,14”
§ Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney > Clinical presentation
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“8 of 13 patients had evidence of renal function recovery”
§ Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney > Outcome
plainn = 13- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median age of initial presentation with TMA was 6 months (range, 2-20 months) (Table 1).”
§ Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney > Clinical presentation
plainn = 13- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no evidence of renal disease in this period (Figure 2b[i] and c[vi]).”
§ Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney > Exosc3 KO mouse
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
23 more claims
Create a free account to see all 50 claims and to verify the 17 references still open.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 13
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney > Clinical presentation
“p.Gly31Arg (allelic frequency 73%) and p.Asp132Ala (allelic frequency 15%), accounted for 88% of the EXOSC3 alleles in the TMA subgroup.”
§ Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney > Cell cycle analysis
“II Gly31Ala; Asp132Ala 8 RSV 88 77 37 9478 MAHA TMA FFP and eculizumab 14 Recovery, 1 relapse 14 III Gly31Ala; Gly31Ala 2 Respiratory 172 61 69 962 MAHA TMA Eculizumab 15 Recovery 4”
Citations
Cites
Iordanov, M. S., Pribnow, D., Magun, J. L., Dinh, T.-H., Pearson, J. A., Chen, S. L.-Y., & Magun, B. E. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.6.3373 · Cited by 492
Wan, J., Yourshaw, M., Mamsa, H., Rudnik-Schöneborn, S., Menezes, M. P., Hong, J. E., Leong, D. W., Senderek, J., Salman, M. S., Chitayat, D., et al. (2012) · Nature Genetics · doi:10.1038/ng.2254 · Cited by 257
Kampen, K. R., Sulima, S. O., Vereecke, S., & De Keersmaecker, K. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz637 · Cited by 214
Noncoding RNA transcription targets AID to divergently transcribed loci in B cells
Pefanis, E., Wang, J., Rothschild, G., Lim, J., Chao, J., Rabadan, R., Economides, A. N., & Basu, U. (2014) · Nature · doi:10.1038/nature13580 · Cited by 201
Self-citationSmith, W. E., Kane, A. V., Campbell, S. T., Acheson, D. W. K., Cochran, B. H., & Thorpe, C. M. (2003) · Infection and Immunity · doi:10.1128/iai.71.3.1497-1504.2003 · Cited by 191
p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways
Lindström, M. S., Bartek, J., & Maya-Mendoza, A. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00999-w · Cited by 159
Pontocerebellar hypoplasia type 1: Clinical spectrum and relevance of EXOSC3 mutations
Rudnik-Schöneborn, S., Senderek, J., Jen, J. C., Houge, G., Seeman, P., Puchmajerová, A., Graul-Neumann, L., Seidel, U., Korinthenberg, R., Kirschner, J., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0f66 · Cited by 103
Tesh, V. L. (2012) · Cellular Microbiology · doi:10.1111/j.1462-5822.2011.01684.x · Cited by 88
Brocklebank, V., Walsh, P. R., Smith-Jackson, K., Hallam, T. M., Marchbank, K. J., Wilson, V., Bigirumurame, T., Dutt, T., Montgomery, E. K., Malina, M., et al. (2023) · Blood · doi:10.1182/blood.2022018833 · Cited by 85
Self-citationGarnier, A., Brochard, K., Kwon, T., Sellier‐Leclerc, A., Lahoche, A., Allain‐Launay, E., Nobili, F., Caillez, M., Taque, S., Harambat, J., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000182 · Cited by 84
Cited by
Still being checked.
Metadata
- Authors
- Walsh, P. R., Basu, U., Barakat, T. S., Beck, B. B., Bertini, E., Brocklebank, V., Corderio, N., Ćomić, J., Abazi-Emini, N., Fluss, J., George, A., Bülow, M., Gibson, B. G., Hambleton, S., Hoefele, J., Hunt, D., Ivanov, I., Johnson, S., Kotzaeridou, U., Laštůvková, J., Lunn, A., Mallett, G., Pappworth, I., Philippou, H., Platzer, K., Robson, J., Šafka brožková, D., Smith-Jackson, K., Sinha, M. D., Thompson, G., Wood, K., Zanni, G., Prohászka, Z., Laubova, J., Aranka, J., Bojtár, Z., Antal-Konya, V., Bologa, C., Karava, V., Kamilari, T., Georgiadou, E., Tasic, V., Markova, P., Marchbank, K. J., & Kavanagh, D.
- Affiliations
- Newcastle University (GB)
- Columbia University (US)
- Erasmus MC (NL)
- University of Cologne (DE)
- Bambino Gesù Children's Hospital (IT)
- NHS Ayrshire and Arran (GB)
- Institut für Humangenetik (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Institute of Genetics and Cancer (GB)
- Medical University Plovdiv (BG)
- University Hospital Heidelberg (DE)
- Nottingham University Hospitals NHS Trust (GB)
- University of Leeds (GB)
- University Hospital Leipzig (DE)
- King's College London (GB)
- Royal Victoria Infirmary (GB)
- Semmelweis University (HU)
- Spitalului Clinic de Urgență pentru Copii Maria Sklodowska Curie (RO)
- National and Kapodistrian University of Athens (GR)
- Ss. Cyril and Methodius University in Skopje (MK)
- Corresponding author
- Kavanagh, David
- ORCID
- Walsh, Patrick R.
- Basu, Uttiya
- Barakat, Tahsin Stefan
- Bertini, Enrico
- Brocklebank, Vicky
- Gibson, Beth G.
- Hambleton, Sophie
- Hoefele, Julia
- Hunt, David
- Johnson, Sally
- Kotzaeridou, Urania
- Lunn, Andrew
- Mallett, Grace
- Pappworth, Isabel
- Philippou, Helen
- Platzer, Konrad
- Sinha, Manish D.
- Thompson, Gemma
- Wood, Katrina
- Zanni, Ginevra
- Prohászka, Zoltán
- Bologa, Cristina
- Karava, Vasiliki
- Markova, Petya
- Marchbank, Kevin J.
- Kavanagh, David
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2026-10
- Volume
- 110
- Issue
- 4
- Pages
- 1013-1021
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W7170035673
- Cited by
- 0
- References
- 24
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Kidney International (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- Funders
- Kidney Research UK (NU-024193)
- Wellcome Trust (BH184374)
- Macular Society
- Idorsia Pharmaceuticals
- Medical Research Council
- Catalyst Biosciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- thrombotic microangiopathy, EXOSC3, RNA exosome, complement inhibition, acute kidney injury, conditional knockout mouse model, neurodevelopmental disorders, cell cycle arrest, apoptosis
- MeSH terms
- Animals, Child, Child, Preschool, Drug Resistance, Europe, Female, Humans, Infant, Kidney, Male, RNA-Binding Proteins, Apoptosis, Mice, Knockout, Complement Inactivating Agents, Mice, Thrombotic Microangiopathies, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney. https://app.cochat.ai/papers/10.1016/j.kint.2026.06.028
- The paper
- Walsh, P. R., Basu, U., Barakat, T. S., Beck, B. B., Bertini, E., Brocklebank, V., Corderio, N., Ćomić, J., Abazi-Emini, N., Fluss, J., George, A., Bülow, M., Gibson, B. G., Hambleton, S., Hoefele, J., Hunt, D., Ivanov, I., Johnson, S., Kotzaeridou, U., . . . Kavanagh, D. (2026). Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney. Kidney International. https://doi.org/10.1016/j.kint.2026.06.028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.